|
Post by iamaverb on Jun 2, 2015 17:38:01 GMT
I loaded up with more at $19 on May 5th, and now 20 trading days later we are up 45%. I have been unloading OCAT for a while and plowing it into this little jewel. Just this morning when ADXS turned red I bought another 1000 shares to make it an even 20K shares. This company has surpassed the profit I made in LVS when it ran from $12 to the $60"s. It makes the pain of having owned a poor quality investment like OCAT a little more bearable. Ok watch, pride cometh before fall, and I have just jinxed it. (hoping not) iamaverb, congrats! That is some serious change$$$! The downside is it requires me to be within arms reach of the laptop throughout the day. I had to turn down a day at the ballpark with the buds this week. Hell, who am I kidding, this is great!
|
|
|
Post by JHam on Jun 4, 2015 16:52:04 GMT
I guess should have bought those shares back at $14 after all. Sheesh, up another 6% today. Fortunately all of my other positions are doing well at the moment, but this one is truly spectacular. Good luck to all of you continuing to hold!
|
|
|
Post by JHam on Jun 8, 2015 13:46:03 GMT
Hey what do you know, ADXS is up another 5% today and just crossed $30 for the first time. Congrats guys!
|
|
|
Post by natureeguy on Jun 8, 2015 14:50:07 GMT
Hey Jham,
So what do you think....this stock is what dreams are made of? :} We should start seeing some milestones being pr'd this month as well. This company does seem to be productive and do what they say. Wouldn't be surprised to see 40 by Fall
|
|
|
Post by selluwud on Jun 8, 2015 14:52:47 GMT
I've been in and out of ADXS several times over the years but I recently got in to stay after the last raise and it dipped into the 16's. I will wait for this company to reach it's end game.
|
|
|
Post by JHam on Jun 8, 2015 15:17:32 GMT
Hey Jham, So what do you think....this stock is what dreams are made of? :} We should start seeing some milestones being pr'd this month as well. This company does seem to be productive and do what they say. Wouldn't be surprised to see 40 by Fall I think it is great! I am sincerely happy for all of you guys who have owned this stock the past few months. It's not every day you find a company that can grow this much in their entire existence, let alone less than a year. I haven't been following ADXS too closely, but nothing at this point would surprise me.
|
|
|
Post by RLC on Jun 8, 2015 16:45:44 GMT
I've been in and out of ADXS several times over the years but I recently got in to stay after the last raise and it dipped into the 16's. I will wait for this company to reach it's end game. Congrats Selluwud! I had contemplated buying in when it traded in the $8-$12 range a while back, but once it got over $20 I just had the "I missed the boat" feel. I continue to keep an eye on ADXS and am rooting for everyone involved in this.
|
|
|
Post by selluwud on Jun 8, 2015 16:49:16 GMT
I've been in and out of ADXS several times over the years but I recently got in to stay after the last raise and it dipped into the 16's. I will wait for this company to reach it's end game. Congrats Selluwud! I had contemplated buying in when it traded in the $8-$12 range a while back, but once it got over $20 I just had the "I missed the boat" feel. I continue to keep an eye on ADXS and am rooting for everyone involved in this. Thanks RLC, I had to get in after being jealous of the folks here who are quietly accumulating a great return without a lot of fanfare. Steady as she goes.
|
|
|
Post by JHam on Jun 9, 2015 14:15:32 GMT
I want to say that it looks like there is a little bit of consolidation taking place the past two days, however now that I said that it will probably go to $35 tomorrow, lol.
|
|
|
Post by selluwud on Jun 17, 2015 17:42:55 GMT
Consensus among analysts staying positive.
Advaxis PT Raised to $30.00 at HC Wainright (ADXS) June 17th, 2015 - 0 comments - Filed Under - by Doug Madison Share on StockTwits
Advaxis logoEquities research analysts at HC Wainright lifted their target price on shares of Advaxis (NASDAQ:ADXS) from $25.00 to $30.00 in a research note issued to investors on Tuesday. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainright’s target price indicates a potential upside of 35.93% from the company’s current price.
Advaxis (NASDAQ:ADXS) opened at 22.07 on Tuesday. Advaxis has a 52-week low of $2.50 and a 52-week high of $30.13. The stock has a 50-day moving average of $22. and a 200-day moving average of $13.. The company’s market cap is $607.10 million.
Advaxis (NASDAQ:ADXS) last posted its quarterly earnings results on Thursday, April 16th. The biotechnology company reported ($0.33) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.31) by $0.02. Analysts expect that Advaxis will post $-1.12 EPS for the current fiscal year.
A number of other firms have also recently commented on ADXS. Analysts at Jefferies Group initiated coverage on shares of Advaxis in a research note on Friday, May 15th. They set a “buy” rating and a $27.00 price target on the stock. Analysts at Janney Montgomery Scott initiated coverage on shares of Advaxis in a research note on Thursday, May 14th. They set a “buy” rating and a $26.00 price target on the stock. Finally, analysts at MLV & Co. initiated coverage on shares of Advaxis in a research note on Thursday, May 14th. They set a “buy” rating and a $34.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average price target of $29.25.
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes, bioengineered to secrete antigen/adjuvant fusion proteins.
|
|
|
Post by natureeguy on Jul 8, 2015 14:59:56 GMT
Another nice hire. However, 85,000 shares? That is a ton of loot! Plus her salary. wow. Anybody have any thoughts about all the Merck hires?
|
|
|
Post by Yelk on Jul 25, 2015 2:36:37 GMT
Now following this company but came up on scans traded it a few times. From a technical perspective we are about to breakout or breakdown soon from this consolidation level. On watch for next week especially Monday with that weak close. Can choose trends either way in the next few days imo. We have been grinding against support for a full month. If starts to bounce will be $2 at least that day and probably hold trend until next news.
Might consider investing some if starts to uptrend will do due diligence that night the convo here looks interesting. Cheers.
|
|
|
Post by runcaly on Sept 14, 2015 19:20:06 GMT
FDA Awards Grant for Phase 2 Study of Axalimogene Filolisbac (ADXS-HPV) in HPV-Associated Head and Neck Cancer Grant Totaling $1.1 Million Over Three Years Awarded to Research Teams at Baylor College of Medicine and Icahn School of Medicine at Mount Sinai Advaxis PRINCETON, N.J., Sept. 14, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development (OOPD) awarded a grant totaling $1.1 million over three years to Baylor College of Medicine in support of an ongoing Phase 2 trial of Advaxis's lead Lm Technology(TM) immunotherapy, axalimogene filolisbac (ADXS-HPV), in HPV-associated oropharynx (throat) cancer, a type of head and neck cancer.
The grant was administered through the FDA's Orphan Products Grants Program, created more than 30 years ago by the Orphan Drug Act to promote the development of products for rare diseases. It is a competitive program that receives approximately 100 applications per year, from which typically 10 to 15 applications are selected for funding each fiscal year.
"Applications to the Orphan Products Grants Program undergo rigorous review for scientific and technical merit by a panel of experts to compete for funding," said Daniel J. O'Connor, President and Chief Executive Officer of Advaxis. "We are encouraged to see axalimogene filolisbac recognized as viable by being awarded a grant for its clinical research that could ultimately contribute to market approval."
The Phase 2 study will be led by Andrew G. Sikora, M.D., Associate Professor of Otolaryngology at BCM and co-director of the Head and Neck Cancer Program in the NCI Comprehensive-Designated Dan L. Duncan Cancer Center at Baylor, and is supported by key investigators Brett Miles, M.D. and Marshall Posner, M.D. at the Icahn School of Medicine at Mount Sinai. The study is designed to evaluate the efficacy of axalimogene filolisbac as neoadjuvant treatment prior to robot-assisted surgery in patients with HPV-associated oropharyngeal cancer.
"We hope to improve outcomes in HPV-associated head and neck cancer by exploring axalimogene filolisbac in this indication, where existing treatment options are associated with risk of long-term morbidity," said Dr. Sikora. "If successful, this trial could pave the way for immunotherapy to become a standard treatment for HPV-associated cancers."
HPV-Associated Oropharynx (Throat) Cancer
Related Quotes ADXS 17.80 +7.81% Advaxis, Inc. Watchlist 17.80+1.29(+7.81%) NASDAQ3:15 PM EDT
|
|
|
Post by observingthechaos on Sept 16, 2015 7:06:38 GMT
The grant was administered through the FDA's Orphan Products Grants Program, created more than 30 years ago by the Orphan Drug Act to promote the development of products for rare diseases. It is a competitive program that receives approximately 100 applications per year, from which typically 10 to 15 applications are selected for funding each fiscal year. NASDAQ3:15 PM EDT Big vote of confidence from the FDA.
|
|
|
Post by iamwhatiam on Sept 18, 2015 1:13:05 GMT
What are everyone's thoughts on the result and pps activity today? Seems like a case of good results but below expectations. That was a wild price swing in the afternoon. What was that? Taking stops out? Engineered panic selling? Someone's making money.
|
|
|
Post by Yelk on Sept 18, 2015 3:43:59 GMT
What are everyone's thoughts on the result and pps activity today? Seems like a case of good results but below expectations. That was a wild price swing in the afternoon. What was that? Taking stops out? Engineered panic selling? Someone's making money. Market is total nuts right now. Things running 100-300% no news. Crashing and squeezing. I've seen this ADXS pattern a lot last couple months. I hope you all stayed safe on this one it halted numerous times which I believe added to the panic and allowed people to take advantage. Often in price is low enough allows for a squeeze when people become too short biased. Question is - where does it go from here.
|
|
|
Post by iamaverb on Sept 29, 2015 17:02:37 GMT
And to think I made a bad decision selling all between the $16 and $19 range. I wish I was more fortunate with OCAT shares.
|
|
|
Post by JHam on Sept 29, 2015 18:48:07 GMT
And to think I made a bad decision selling all between the $16 and $19 range. I wish I was more fortunate with OCAT shares. Things are really strange right now across the board with biotechs. If I can figure out this anomaly I'll let you know Congrats on getting out when you did though.
|
|
|
Post by Yelk on Oct 6, 2015 20:32:56 GMT
ADXS Destroyed after hours so far on news of clinical hold 4 programs from FDA. SHould bounce some but nasty business so far. Might be buying opp? Will be watching on sidelines. Stay safe!
|
|
|
Post by natureeguy on Oct 7, 2015 0:41:35 GMT
Heavy sigh. Well, management seems pretty confident that it's not going to be a problem. If it drops significantly I think I will load up more. Hopefully it doesn't bite me, but I still have confidence in the CEO. They are advertising 12 positions, including a patent attorney. Some good things seem to be coming. Guess we will find out shortly.
|
|